BANK VONTOBEL/PUT/ROCHE GS/260/0.1/19.07.24 Share Price

Warrant

DE000VD8HSH4

Real-time Boerse Frankfurt Warrants 09:33:59 01/07/2024 BST
1.08 EUR -8.47% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/260/0.1/19.07.24
Date Price Change
01/07/24 1.08 -8.47%
28/06/24 1.18 +8.26%
27/06/24 1.09 -8.40%
26/06/24 1.19 +48.75%
25/06/24 0.8 +8.11%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 09:33 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VD8HSH
ISINDE000VD8HSH4
Date issued 21/06/2024
Strike 260 CHF
Maturity 19/07/2024 (19 Days)
Parity 10 : 1
Emission price 1.09
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 1.19
Lowest since issue 0.73
Spread 0.01
Spread %0.92%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus